Literature DB >> 30186438

Improved heart failure by Rhein lysinate is associated with p38MAPK pathway.

Wei Wang1, Xin Meng1, Jing Wang1, Yong Li1.   

Abstract

The present study aimed to explore the role of Rhein lysinate (RHL) in neonatal rat ventricular myocytes (NRVMs) and congestive heart failure induced by co-arctation of the abdominal aorta. Male Sprague-Dawley rats were divided into 3 groups randomly: co-arctation of abdominal aorta group (A group, n=10), sham operation group (SH group, n=10) and RHL treatment rats (A+RHL group, n=10). To establish an in vitro oxidative stressed cardiomyocyte model, NRVMs were treated with 10 µM H2O2 for 24 h. MTT assay indicated that H2O2 treatment reduced primary cardiomyocyte viability in a time- and dose- dependent manner, whereas RHL abolished the detrimental effects of H2O2, indicating a protective role of RHL. Further study demonstrated that H2O2-induced reactive oxygen species (ROS) production was reversed by RHL. Then, TUNEL staining was carried out and the results revealed that H2O2 markedly enhanced primary cardiomyocyte apoptosis. Conversely, RHL incubation decreased H2O2-induced cell apoptosis, indicating the protective role of RHL in primary cardiomyocytes. Furthermore, abnormal p38 activation was identified in the failed heart. Notably, treatment with RHL reduced p38 activation. In addition, RHL significantly enhanced the expression of anti-apoptotic protein, B cell lymphoma (Bcl)-2, however markedly reduced the protein level of Bcl-2 associated X, apoptosis regulator in primary cardiomyocytes, indicating its anti-apoptotic role in the cardiac setting. Overall, RHL protects heart failure primarily by reducing ROS production and cardiomyocyte apoptosis via suppressing p38 mitogen activated protein kinase activation.

Entities:  

Keywords:  Rhein lysinate; apoptosis; heart failure; p38MAPK

Year:  2018        PMID: 30186438      PMCID: PMC6122205          DOI: 10.3892/etm.2018.6423

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

1.  Heart failure not responsive to standard immunosuppressive therapy is successfully treated with high dose intravenous immunoglobulin therapy in a patient with Eosinophilic Granulomatosis with Polyangiitis (EGPA).

Authors:  Antonio Pecoraro; Ludovica Crescenzi; Laura Carucci; Arturo Genovese; Giuseppe Spadaro
Journal:  Int Immunopharmacol       Date:  2017-01-31       Impact factor: 4.932

2.  Heart failure and diabetes - underestimated, underdiagnosed and poorly understood: A call for action.

Authors:  Nikolaus Marx
Journal:  Diab Vasc Dis Res       Date:  2017-01-27       Impact factor: 3.291

Review 3.  Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction.

Authors:  Michele Senni; Emilia D'Elia; Michele Emdin; Giuseppe Vergaro
Journal:  Handb Exp Pharmacol       Date:  2017

Review 4.  Heart failure with preserved ejection fraction: Defining the function of ROS and NO.

Authors:  Li Zuo; Chia-Chen Chuang; Benjamin T Hemmelgarn; Thomas M Best
Journal:  J Appl Physiol (1985)       Date:  2015-05-14

5.  Regulation of ribosomal DNA transcription during contraction-induced hypertrophy of neonatal cardiomyocytes.

Authors:  R D Hannan; J Luyken; L I Rothblum
Journal:  J Biol Chem       Date:  1996-02-09       Impact factor: 5.157

6.  Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes.

Authors:  Yoko Irukayama-Tomobe; Takashi Miyauchi; Yoshitoshi Kasuya; Satoshi Sakai; Katsutoshi Goto; Iwao Yamaguchi
Journal:  J Cardiovasc Pharmacol       Date:  2004-11       Impact factor: 3.105

7.  The protection of Rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin.

Authors:  Ya-Jun Lin; Gang Hu; Kai-Ji Li; Yu-Fang Zhao; Jie Wei; Yong-Zhan Zhen
Journal:  Arch Pharm Res       Date:  2014-06-28       Impact factor: 4.946

8.  Enhanced ROS production by NADPH oxidase is correlated to changes in antioxidant enzyme activity in human heart failure.

Authors:  Elisabetta Borchi; Valentina Bargelli; Francesca Stillitano; Carla Giordano; Mariangela Sebastiani; Paolo Antonio Nassi; Giulia d'Amati; Elisabetta Cerbai; Chiara Nediani
Journal:  Biochim Biophys Acta       Date:  2009-11-03

9.  Correlations between MTP and ROS Levels of Peripheral Blood Lymphocytes and Readmission in Patients with Chronic Heart Failure.

Authors:  Bingxue Song; Tao Li; Shuping Chen; Dandan Yang; Ling Luo; Tingzhong Wang; Xiu Han; Ling Bai; Aiqun Ma
Journal:  Heart Lung Circ       Date:  2015-10-09       Impact factor: 2.975

Review 10.  The case for inhibiting p38 mitogen-activated protein kinase in heart failure.

Authors:  Pelin Arabacilar; Michael Marber
Journal:  Front Pharmacol       Date:  2015-05-12       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.